Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective
Immunotherapy has revolutionized cancer treatment and brought new aspects into tumor immunology. Effective immunotherapy will require using the suitable target antigens, optimizing the interaction between the antigenic peptide, the APC, and the T cell, and the simultaneous inhibitor of the negative regulatory process that inhibits immunotherapeutic effects and develop resistance. Tumor heterogeneity and its microenvironment is the leading cause of resistance in patients. Recently by emerging the single-cell RNA sequencing technology and its combination with immunotherapy, now we can specifically evaluate the mechanism of tumors in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and other important processes. This review focuses on scRNA-seq, particularly on its application in cancer immunotherapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:146 |
|---|---|
| Enthalten in: |
Biomedicine & Pharmacotherapy - 146(2022), Seite 112558- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nafiseh Erfanian [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Cancer |
|---|
| doi: |
10.1016/j.biopha.2021.112558 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ074077104 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ074077104 | ||
| 003 | DE-627 | ||
| 005 | 20230309122445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2021.112558 |2 doi | |
| 035 | |a (DE-627)DOAJ074077104 | ||
| 035 | |a (DE-599)DOAJ3a3b03c7b3ba4097ba954f2541d34599 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Nafiseh Erfanian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Immunotherapy has revolutionized cancer treatment and brought new aspects into tumor immunology. Effective immunotherapy will require using the suitable target antigens, optimizing the interaction between the antigenic peptide, the APC, and the T cell, and the simultaneous inhibitor of the negative regulatory process that inhibits immunotherapeutic effects and develop resistance. Tumor heterogeneity and its microenvironment is the leading cause of resistance in patients. Recently by emerging the single-cell RNA sequencing technology and its combination with immunotherapy, now we can specifically evaluate the mechanism of tumors in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and other important processes. This review focuses on scRNA-seq, particularly on its application in cancer immunotherapy. | ||
| 650 | 4 | |a ScRNA-seq | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Immune checkpoints | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Afshin Derakhshani |e verfasserin |4 aut | |
| 700 | 0 | |a Saeed Nasseri |e verfasserin |4 aut | |
| 700 | 0 | |a Mohammad Fereidouni |e verfasserin |4 aut | |
| 700 | 0 | |a Behzad Baradaran |e verfasserin |4 aut | |
| 700 | 0 | |a Neda Jalili Tabrizi |e verfasserin |4 aut | |
| 700 | 0 | |a Oronzo Brunetti |e verfasserin |4 aut | |
| 700 | 0 | |a Renato Bernardini |e verfasserin |4 aut | |
| 700 | 0 | |a Nicola Silvestris |e verfasserin |4 aut | |
| 700 | 0 | |a Hossein Safarpour |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Biomedicine & Pharmacotherapy |d Elsevier, 2021 |g 146(2022), Seite 112558- |w (DE-627)DOAJ078596181 |x 19506007 |7 nnns |
| 773 | 1 | 8 | |g volume:146 |g year:2022 |g pages:112558- |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.biopha.2021.112558 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/3a3b03c7b3ba4097ba954f2541d34599 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0753332221013457 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0753-3322 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 146 |j 2022 |h 112558- | ||